XL EVI1

Break Apart Probe - Triple Color

Order Number
D-5036-100-TC
Package Size
100 µl
Labels
   
Chromosome
3

Description

XL EVI1

This product has been replaced by XL MECOM 3q26. Order Number D-5059-100-OG

Clinical Details

The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

Chromosomal translocations involving the MECOM locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis. Two common recurrent rearrangements affect the 3q26 locus. One is the inv(3)(q21q26) and the translocation t(3;3)(q21;q26), in which EVI1 overexpression is caused by juxtaposition of the EVI1 gene to enhancer elements of the Ribophorin gene at 3q21. EVI1 activation is also observed in the translocations t(3;12)(q26;p13) and t(3;21)(q26;q22) and is due to generation of the fusion genes ETV6/EVI1 and RUNX1/EVI1, respectively.

Clinical Applications

  • Myelodysplastic Syndrome (MDS)
  • Acute Myelogenous Leukemia (AML)

Images

XL EVI1

XL EVI1 hybridized to lymphocytes. A normal interphase is displayed with two blue-green-orange fusion signals.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two blue-green-orange (2BGO) fusion signals representing the two normal EVI1 loci.

Expected Pattern 2

Aberrant Cell (typical results):
One green-blue (1GB) signal and one separate orange (1O) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.

Expected Pattern 3

Aberrant Cell (typical results): One green-orange (1GO) signal and one separate blue (1B) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.

Literature

  • De Melo et al (2007) Leukemia 22:434-437
  • De Wer et al (2008) Haematologica 93:1903-1907
  • De Braekeleer et al (2015) Future Oncology 11:1675-1686

Downloads

Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.